Codexis Posts $15.7M Q3 Product Revenue, Narrower $8.1M Net Loss
CDXS is trading near its 52-week low of $0.9 (11% above the low).
Summary
Codexis reported Q3 revenue of $19.3 million, with product revenue of $15.74 million, up from the $13.2 million booked in Q2, a net loss of $8.128 million and basic EPS of -$0.08. The operating loss came in at $7.436 million and the pretax loss at $8.119 million. The revenue line is the key read: product sales are the growth engine the company has been leaning on, and this quarter extends the Q2 momentum. The loss is smaller than Q2's $12.0 million net loss, so the burn is trending the right way. The company also reiterated its 2026 revenue guidance. This lands days after the Nov 10 announcement of a $60 million senior secured term loan with Trinity Capital, of which $42.5 million was drawn to retire the Innovatus debt — liquidity is the story alongside the top line.
At the time of this announcement, CDXS was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $104.9M. The 52-week trading range was $0.90 to $2.98. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.